Rethinking Pharma Commercial Targeting with AI - with Philip Poulidis of ODAIA
Commercial life‑sciences teams are facing a widening gap between strong brand strategy and fragmented real‑world execution, driven by misaligned workflows, static targeting, and an inability to act at the speed patients move through their therapeutic journeys. In this episode, Philip Poulidis, CEO and Co-founder of ODAIA, unpacks how AI can close that gap by connecting brand intent to real‑time execution, enabling teams to prioritize the right HCPs, orchestrate engagement, and measure impact through outcomes rather than activity metrics. He highlights …
Kāore anō kia whakamāoritia tēnei wāhanga
Ka whakamahia te STT.ai hei whakahua i tēnei wāhanga me te AI. Ka whiwhi tuhipānui tika me te kite kaikōrero, ngā tātaitai wā, me te kawe mai i ngā hanga maha.